• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YANG Lan, GE Qiufu, GUO Dianwu, XU Weiliang, ZHAO Li. Antitumor effects and the mechanisms of dual-targeting drug NL-101 on human multiple myeloma[J]. Journal of China Pharmaceutical University, 2017, 48(4): 469-475. DOI: 10.11665/j.issn.1000-5048.20170412
Citation: YANG Lan, GE Qiufu, GUO Dianwu, XU Weiliang, ZHAO Li. Antitumor effects and the mechanisms of dual-targeting drug NL-101 on human multiple myeloma[J]. Journal of China Pharmaceutical University, 2017, 48(4): 469-475. DOI: 10.11665/j.issn.1000-5048.20170412
shu

Antitumor effects and the mechanisms of dual-targeting drug NL-101 on human multiple myeloma

More Information
    Graphical Abstract
    • Abstract
  • The antitumor activities of NL-101, aHDACi/DNA damage dual-targeting drug, on human multiple myeloma in vitro and in vivo were studied. Furthermore, the primary mechanisms were revealed. We detected the anti-proliferative activity of NL-101 on 10 human multiple myeloma cell lines, and the combinational effect of NL-101 and bortezomib on RPMI 8226 cell line. The inducing effects of NL-101 on cell cycle arrest and apoptosis were detected by FACS. The effects of NL-101 on acetyled-Histone H3, total Histone H3, acetyled α-Tubulin, total α-Tubulin, phospho-Histone H2A. X and total Histone H2A. X were evaluated by Western blott. We also demonstrated the antitumor activity of NL-101 and the combinational effect of NL-101 and bortezomib on RPMI 8226 xenograft tumor model in vivo. Results showed that NL-101 possessed strong antitumor activities on human multiple myeloma cells in vitro and in vivo. NL-101exhibited significant HDAC inhibitory activity and DNA alkylating activity. NL-101not only inhibited histone deacetylation level, but also increased the DNA damage in multiple myeloma cells. Meanwhile, NL-101 induced cell cycle arrest and apoptosis. Also, the synergistic effect of NL-101 was discovered when combined with bortezomib in vitro and in vivo. These data demonstrated that NL-101 may be a potent agent for the treatment of human multiple myeloma in future.
    • FullText(HTML)
    • References (11)
  • [1]
    Manal M,Chandrasekar MJ,Gomathi Priya J.Inhibitors of histone deacetylase as antitumor agents:a critical review[J].Bioorg Chem,2016,67:18-42.
    [2]
    Groselj B, Sharma NL, Hamdy FC, et al. Histonedeacetylase inhibitors as radiosensitisers:effects on DNA damage signalling and repair[J]. Bri J Cancer,201,108(4):748-754.
    [3]
    Sanchez E, Shen J, Steinberg J, et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo[J].Leuk Res,2011,35:373-379.
    [4]
    Lee CK,Wang S,Huang X,et al.HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells[J].Cancer Lett,2010,296:233-240.
    [5]
    Ai T,Cui H,Chen L.Multi-targeted histone deacetylase inhibitors in cancer therapy[J].Curr Med Chem,2012,19:475-487.
    [6]
    Cai B,Lyu H,Huang J,et al.Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response[J].Cancer Lett,2013,335:343-350.
    [7]
    Mehrling T,Chen Y.The alkylating-HDAC inhibition fusion principle:taking chemotherapy tothe next level with the first in class molecule EDO-S101[J].Anticancer Agents Med Chem,2016,16(1):20-28.
    [8]
    Yu J,Qiu S,Ge Q,et al.A novel SAHA-bendamustinehybridinduces apoptosis of leukemia cells[J].Oncotarget,2015,6(24):20121-20131.
    [9]
    Gentile M,Vigna E,Recchia AG,et al.Bendamustine in multiple myeloma[J].Eur J Haematol,2015,95(5):377-388.
    [10]
    Dimopoulos M,Siegel DS,Lonial S,et al.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma(VANTAGE 088):a multicentre,randomised,double-blind study[J].Lancet Oncol,2013,14(11):1129-1140.
    [11]
    Yalon M,Tuval-Kochen L.Overcoming resistance of cancer cells to PARP-1 Inhibitors with three different drug combinations[J].PLoS ONE,2016,11(5):e0155711.
    • Related Articles

  • Related Articles

    [1]LIU Xiaohan, TAN Yunying, LI Qiang, CHEN Xu, FU Junjie, YIN Jian. Synthesis and antitumor activity evaluation of glycoconjugates derived from natural product harmine[J]. Journal of China Pharmaceutical University, 2023, 54(6): 729-742. DOI: 10.11665/j.issn.1000-5048.2023041101
    [2]SUN Dongyu, GONG Jingxu, LI Xuwen, HAN Guanying, GUO Yuewei. Studies on methyl xestopongoate analogues:design, synthesis and antitumor activities[J]. Journal of China Pharmaceutical University, 2018, 49(4): 413-421. DOI: 10.11665/j.issn.1000-5048.20180405
    [3]QIAO Yixue, MOU Yi, HUANG Zhangjian, AI Yong, KANG Fenghua, LAI Yisheng, ZHANG Yihua. Synthesis and antitumor activities of novel CDDO-Me analogues[J]. Journal of China Pharmaceutical University, 2015, 46(3): 289-293. DOI: 10.11665/j.issn.1000-5048.20150305
    [4]GU Xiaoke, TANG Xiaobo, HUANG Zhangjian, PENG Hui, ZHANG Yihua. Synthesis and antitumor activity of NO-releasing alkoxylbiphenyl derivatives[J]. Journal of China Pharmaceutical University, 2014, 45(6): 657-661. DOI: 10.11665/j.issn.1000-5048.20140606
    [5]HU Kun, ZHOU Anfei, JIANG Hefei, XU Yuanyuan, HUANG Qianhui, YANG Jie, CHEN Xin, REN Jie. Synthesis and antitumor activities of podophyllotoxin derivatives[J]. Journal of China Pharmaceutical University, 2014, 45(1): 33-38. DOI: 10.11665/j.issn.1000-5048.20140105
    [6]LIU Dexiu, PAN Huaying, SHI Hui, HUANG Xiaoying, LOU Hongxiang. Synthesis and antitumor activity of a novel bisbibenzyl derivative[J]. Journal of China Pharmaceutical University, 2013, 44(6): 515-519. DOI: 10.11665/j.issn.1000-5048.20130605
    [7]HU Kun, XU Hua-jin, XIN Wen-qun, CHEN Xin, REN Jie. Synthesis and antitumor activity of nitrogen mustard derivatives of formononetin[J]. Journal of China Pharmaceutical University, 2012, 43(2): 113-119.
    [8]ZHA Xiao-ming, ZHANG Fei-ran, SHAN Jia-qi, CHEN Yan-ke, ZHANG Yi-hua, LIU Jun, SUN Hong-bin. Synthesis and in vitro antitumor activities of novel soladulcidine derivatives[J]. Journal of China Pharmaceutical University, 2010, 41(6): 493-498.
    [9]Synthesis and antitumor activity of ent-kaurene diterpenoids[J]. Journal of China Pharmaceutical University, 2010, 41(1): 20-25.
    [10]ZHOU Mei, MA Lin, HAO Xiao-jiang, YANG Xiao-sheng. Antitumor activities of chemical constituents of Cephalotaxus fortunei in Guizhou province[J]. Journal of China Pharmaceutical University, 2009, 40(3): 209-212.

Catalog

    Get Citation
    PDF
    XML
    Article views (839) PDF downloads (2164) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365505

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return